|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.740 USD | -3.87% |
|
-.--% | - |
| 11-21 | Xoma Royalty Completes Acquisition of Lava Therapeutics | MT |
| 11-21 | Xoma Royalty announces closing of transactions to acquire LAVA Therapeutics N.V. | RE |
Company Valuation: LAVA Therapeutics
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Market Cap 1 | 141.8 | 92.01 | 41.54 | 25.01 |
| Change | - | -35.1% | -54.86% | -39.79% |
| Enterprise Value (EV) 1 | 13.43 | -35.41 | -47.72 | -46.28 |
| Change | - | -363.69% | -34.78% | 3.01% |
| P/E | -2.4x | -2.84x | -1.01x | -1.02x |
| PBR | 1.2x | 1.07x | 0.81x | 0.9x |
| PEG | - | 0.1x | -0x | 0x |
| Capitalization / Revenue | 28,353,092x | 4,745,078x | 6,136,321x | 2,087,300x |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | -0.31x | 1.03x | 1.12x | 1.83x |
| EV / EBIT | -0.3x | 1.02x | 1.1x | 1.79x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Dividend per Share 3 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 3 | -2.295 | -1.231 | -1.57 | -0.9359 |
| Distribution rate | - | - | - | - |
| Net sales | 5 | 19.39 | 6.769 | 11.98 |
| EBITDA 1 | -44.02 | -34.33 | -42.64 | -25.33 |
| EBIT 1 | -44.35 | -34.84 | -43.25 | -25.79 |
| Net income 1 | -45.35 | -31.91 | -41.97 | -25.11 |
| Net Debt 1 | -128.3 | -127.4 | -89.26 | -71.3 |
| Reference price 3 | 5.500 | 3.500 | 1.580 | 0.951 |
| Nbr of stocks (in thousands) | 25,776 | 26,289 | 26,289 | 26,299 |
| Announcement Date | 3/24/22 | 4/11/23 | 3/20/24 | 3/28/25 |
1USD in Million2EUR in Million3USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 45.77M | |
| 33.6x | 6x | 17.84x | 0.95% | 49.47B | |
| -21.68x | 304.44x | -21.6x | -.--% | 43.97B | |
| 46.07x | 5.25x | 28.89x | -.--% | 39.6B | |
| 30.74x | 3.05x | 13.16x | -.--% | 39.29B | |
| 30.33x | 8.75x | 21.99x | 0.38% | 32.43B | |
| 33.59x | 5.5x | 24.99x | -.--% | 16.49B | |
| 23.22x | 2.04x | 8.82x | 1.16% | 14.01B | |
| 65.72x | 3.81x | 14.73x | -.--% | 12.77B | |
| Average | 30.20x | 42.35x | 13.60x | 0.31% | 27.56B | |
| Weighted average by Cap. | 25.98x | 58.31x | 12.22x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- LVTX Stock
- Valuation LAVA Therapeutics
Select your edition
All financial news and data tailored to specific country editions
